Đang chuẩn bị liên kết để tải về tài liệu:
Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. | Final results from IMPROVE A randomized controlled open-label two-arm cross-over phase IV study to determine patients preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive HER2-negative breast cancer

TÀI LIỆU LIÊN QUAN

The relationship between students’ intrinsic motivation and the final exam results of a student on English subject

Báo cáo y học: "The Factors Influencing Depression Endpoints Research (FINDER) study: final results of Italian patients with depressio"

Economic benefits of standardization Summary of results Final report and practical examples

Preliminary results on prompt ξ-ξ − production ratio in pp collisions at √ s = 7 tev

Testing combined application of ultraviolet and ultrasonic disinfection of wastewater

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: Final results of a noninterventional study

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: Final results from phase II AIO KRK 0105 trial

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.